Explore

Health Official's Ties to Palantir Raise Concerns Over NHS Contract

Health Official's Ties to Palantir Raise Concerns Over NHS Contract

A top health official, Samantha Jones, who serves as the Department of Health and Social Care's most senior civil servant, has come under scrutiny for her connections with Palantir, a US surveillance tech firm. This relationship was highlighted during Palantir's bid for a £330 million contract with the NHS. Jones was an adviser to Carnall Farrar, a consultancy part of a consortium with Palantir, at the time of the contract negotiations. Critics, including Dr. Tony O'Sullivan of Keep Our NHS Public, have labeled the situation as a 'revolving door of corruption,' citing potential conflicts of interest. The contract, awarded in November 2023, involves aggregating NHS patient information. Concerns have been raised about the transparency and ethical implications of this deal, especially given Palantir's controversial human rights record.

Health Insurers Support Vaccination Amidst MAHA Policy Changes to Prevent Measles Outbreaks

Health Insurers Support Vaccination Amidst MAHA Policy Changes to Prevent Measles Outbreaks

Health insurers in the U.S. have committed to covering routine vaccines through 2027, despite the Trump administration's efforts to alter childhood vaccine recommendations under the Make America Healthy Again (MAHA) agenda. The administration aims to reduce the number of recommended childhood vaccines, but insurers recognize the cost-effectiveness of vaccines in preventing expensive outbreaks. This stance by insurers is seen as a market-based endorsement of vaccination, highlighting the financial benefits of preventing diseases like measles, which can incur significant public health costs.

Institut Pasteur Launches ACT-CHIK to Advance Chikungunya Vaccine Development in Africa

Institut Pasteur Launches ACT-CHIK to Advance Chikungunya Vaccine Development in Africa

Institut Pasteur has initiated a four-year research project named ACT-CHIK, aimed at advancing the development of a chikungunya vaccine in Africa. Funded by the Global Health EDCTP3 Joint Undertaking under the European Union’s Horizon Europe program, the project has received €15.3 million to support large-scale Phase Ib/III clinical trials in Rwanda, Kenya, Nigeria, and Senegal. The vaccine, MV-CHIK, is a measles-virus-based candidate originally developed at Institut Pasteur. The initiative seeks to address the growing burden of chikungunya, a mosquito-borne viral disease, by generating critical clinical data and preparing for regional vaccine manufacturing. The project also aims to transfer vaccine manufacturing technology to the Institut Pasteur de Dakar, Africa’s only WHO-prequalified vaccine manufacturer.

JW Vines Medical Society Seeks to Address Doctor Shortage in Inland Empire

JW Vines Medical Society Seeks to Address Doctor Shortage in Inland Empire

The JW Vines Medical Society, a nonprofit organization, is actively recruiting doctors of color to address a significant shortage of medical professionals in the Inland Empire, as highlighted by a study from UC Riverside. The region is identified as one of the most underserved in the United States, with a pressing need for healthcare providers. The initiative aims to improve healthcare access and quality for the diverse population in the area by increasing the number of practicing physicians who can provide culturally competent care.

University of Maryland Researchers Develop Promising Dual Lassa-Rabies Vaccine

University of Maryland Researchers Develop Promising Dual Lassa-Rabies Vaccine

Researchers at the University of Maryland School of Medicine's Center for Vaccine Development and Global Health have reported promising interim results from a clinical trial testing a new dual vaccine against Lassa fever and rabies. The vaccine, known as LASSARAB, was found to be safe and induced immune responses against both viruses. This development is significant as there are currently no vaccines available for Lassa fever, a disease identified by the World Health Organization as a public health threat in Western Africa. The trial involved 54 healthy adult volunteers from the Baltimore area, who received different doses of the vaccine. The results showed that LASSARAB was safe, with no serious adverse events reported, and it induced robust antibody responses against both Lassa and rabies viruses.

UK reviewing Palantir's NHS contract amid pressure to use break clause

UK reviewing Palantir's NHS contract amid pressure to use break clause

LONDON, June 9 (Reuters) - Britain is conducting a full review of its National Health Service contract with U.S. data analytics firm Palantir, amid growing political pressure for the government to use a break clause at the end of the initial term in early 2027.

Study Reveals Most Americans Fall Short on Flavanol Intake for Heart Health

Study Reveals Most Americans Fall Short on Flavanol Intake for Heart Health

Study Reveals Most Americans Fall Short on Flavanol Intake for Heart Health

Community Pharmacy Reform Discussions to Begin by End of June

Community Pharmacy Reform Discussions to Begin by End of June

Community Pharmacy Reform Discussions to Begin by End of June

Experimental Vaccine LASSARAB Shows Promise in Human Trial for Lassa Fever and Rabies

Experimental Vaccine LASSARAB Shows Promise in Human Trial for Lassa Fever and Rabies

Researchers from Thomas Jefferson University and the University of Maryland School of Medicine have reported promising results from the first human clinical trial of LASSARAB, an experimental vaccine designed to protect against both Lassa fever and rabies. Published in Nature Medicine, the study indicates that the vaccine was well tolerated and induced strong immune responses in healthy adult volunteers. Lassa fever is a severe hemorrhagic disease endemic to parts of West Africa, causing significant morbidity and mortality. The LASSARAB vaccine uses an inactivated rabies virus vector to express the Lassa virus glycoprotein complex, leveraging the rabies vaccine's established safety and distribution networks. In a randomized Phase 1 trial, 54 adults received varying doses of LASSARAB or a licensed rabies vaccine as a control. The vaccine demonstrated a robust immune response, with all recipients developing Lassa virus-specific antibodies and achieving protective levels of rabies virus-neutralizing antibodie...

Experimental Vaccine LASSARAB Shows Promise in Human Trials

Experimental Vaccine LASSARAB Shows Promise in Human Trials

Researchers from Thomas Jefferson University and the University of Maryland School of Medicine have reported successful results from the first human clinical trial of LASSARAB, an experimental vaccine designed to protect against both Lassa fever and rabies. The trial, published in Nature Medicine, demonstrated that the vaccine was well tolerated and induced strong immune responses in healthy adult volunteers. Lassa fever is a severe disease endemic to parts of West Africa, causing significant morbidity and mortality. The LASSARAB vaccine uses an inactivated rabies virus vector to express the Lassa virus glycoprotein, leveraging the rabies vaccine's established safety and distribution networks.

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden

Highly effective prevention drug arrives in South Africa, which has world's highest HIV burden

South Africa is rolling out lenacapavir, a twice-yearly injectable drug for HIV prevention that the president calls a turning point in a country with the world’s highest burden of HIV

AMA Launches Campaign to Rebuild Trust in Medicine Amid Misinformation Concerns

AMA Launches Campaign to Rebuild Trust in Medicine Amid Misinformation Concerns

The American Medical Association (AMA) is set to launch a national campaign titled 'Have You Asked Your Doctor?' aimed at combating health misinformation and rebuilding trust in medicine and science. This initiative comes in response to growing vaccine skepticism and misinformation, partly attributed to the Trump administration and figures like Robert F. Kennedy Jr. The campaign will focus on reinforcing the importance of evidence-based medical practices and the expertise of physicians. The AMA has been vocal against changes in vaccine schedules and other public health measures that it believes undermine scientific integrity.